Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchs show that cholesterol-lowering drugs cut heart attacks by more than a quarter

12.10.2007
A study into the use of cholesterol-lowering drugs has found they reduce heart attacks by more than 25 per cent.

The 15-year investigation, by researchers from the University of Glasgow, has shown that patients treated with statins for five years suffer 27 per cent fewer non-fatal heart attacks or deaths due to heart disease.

It appears that the statin treatment reduces the rate occurrence of heart disease events, even after patients stop taking the drug.

Professor Ian Ford, who led the study, said: “We believe that this remarkable ongoing benefit is due to a stabilizing of existing disease in the coronary arteries and significant slowing of further progression of disease. This benefit appears to have persisted for 10 years and may have conferred a lifelong advantage on those treated with the statin.”

The results are published in the New England Journal of Medicine.

The investigation was carried out by the same team who produced the landmark 1995 study that opened the door worldwide for patients to be treated with a statin.

The West of Scotland Coronary Prevention Study followed volunteers over a 15-year period to investigate the treatment benefits and assess the long-term safety of statin use.

The first results of the study, published in 1995, showed that the risk of death from coronary heart disease or non-fatal heart attack was reduced significantly in men who were prescribed a statin for five years.

A total of 6595 Scottish middle-aged men, who had high cholesterol levels but who had not previously suffered a heart attack, were used in the study. One half of the group were prescribed a statin, while the others were given a placebo.

These patients have now been followed for 15 years and provided the basis for the latest findings.

Professor Ford said: “The results of the follow-up provide strong support for the safety of five years of statin use.

“When fatal and non-fatal heart disease events were studied, it was found that, despite the fact that most of the participants were not treated with a statin after the first five years of the trial there was evidence of the group originally receiving the statin continuing to be at lower risk of having a heart disease event.

“In fact, remarkably, five years of treatment with a statin resulted in 27 per cent fewer non-fatal heart attacks or deaths due to heart disease over the period of 15 years. There was a significant 12 per cent reduction in deaths over the entire period, with deaths due to heart disease reduced by 22 per cent.

“This suggests that statin treatment has a long-term beneficial effect in slowing the development of coronary artery disease.”

Professor Stuart Cobbe, lead cardiologist in the study, said: “We were very surprised to find that patients who had been treated for 5 years with a statin continued to have significantly fewer heart attacks and other coronary events compared to those treated with a placebo treatment. This benefit appeared to extend at least 10 years after the original trial.

“These results are very reassuring for patients who might be concerned about safety when taking a drug for a very long period of time. There was no evidence of adverse health problems associated with taking a statin for 5 years.

“Importantly, the relative risk reduction in the 10 years after the trial was lower than that observed during the trial, suggesting that there is still additional benefit from continuing to take statin treatment beyond 5 years. The researchers emphasize therefore that this research does not suggest that patients should stop taking their treatment after five years.

Professor Chris Packard, an expert on cholesterol lowering drugs, said: “The impact of statin treatment appeared to persist long after the active phase of the trial. This suggests that the drugs have lasting beneficial effects on the artery wall possibly by stabilising plaques that might be about to rupture and cause a heart attack.

“What is also important to note is that we made use of the electronic records that Scotland has held for hospital admissions, cancer registrations and deaths since the early 1980s. This study, based on following up participants’ electronic medical records, demonstrates the significant benefits that such records can provide for medical researchers. This Scottish resource is unique in the UK and is equalled in very few places worldwide.”

The research was supported by a research grant from the Chief Scientist Office, Scotland.

Martin Shannon | alfa
Further information:
http://www.gla.ac.uk

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>